Mar 15, 2023

Real Endpoints sponsoring the InformaConnect Access USA 2023 meeting in Philadelphia

The Real Endpoints team is pleased to sponsor the InformaConnect Access USA meeting in Philadelphia next week. We’re showcasing RE Assist, a tech-enabled platform that simplifies the process of finding copay assistance for Medicare patients.

Mar 14, 2023

A “Netflix” – Like Subscription Model For Financing Hepatitis C Treatment

For those mulling the Biden administration's plan to eliminate hepatitis C infection, here's a trip back in time to 2018, to one of the first papers talking about Netflix-style models for drug payment.

Mar 14, 2023

Successful innovative contract according to Jeff Berkowitz:

The three essential components to a successful innovative contract according to Jeff Berkowitz: 1. focus on real and meaningful patient outcomes 2. provide the payer with meaningful value 3. make it simple and easy to execute

Mar 13, 2023

2023 Pharmacy Benefit Conference

Rob O'Brien in action at a March 8 Employers Health conference. With payers creating access barriers to many new therapies (specialty meds, here's looking at you), influencing employers' coverage decisions is a top priority for many drug companies. It's a tricky proposition, though.

Mar 13, 2023

The drug industry’s personalized medicine problem

An important topic given the number of drugs that require a diagnostic for use. @Real Endpoints will dive deeper into this topic at BIO in June, just fyi.

Jan 10, 2023

Amgen’s Horizon acquisition and the demand/competition/price equation

Consider the most successful drug launches of the past few years. The Covid vaccines, of course. But more interesting: the unexpected success of Tepezza, from Horizon, which is being acquired by Amgen.

Jan 10, 2023

News from across the pond with ramifications for US pricing

Jan 10, 2023

An important reality check about innovations like gene editing

The guest essay in the New York Times from Fyodor Urnov is an important reality check about how far we have come - and how far we still need to go - to make innovations like gene editing a reality.

Jan 10, 2023

ALS patients contend with $158K price tag on new drug

ALS patients reacted to excitement when the first drug to slow disease progression and functional decline was approved earlier this year. But as this article reminds, despite the fact that the ALS community has worked diligently to change the Medicare policy, a coverage gap still exists.

Jan 10, 2023

The Real Endpoints team wishes you a happy, healthy, and peaceful holiday season!

In lieu of gifts this holiday season, Real Endpoints has donated to the American Cancer Society in recognition of the life-changing advances our clients bring to market.